Valneva: Chikungunya Candidate Submission Application for FDA Completed
02/20/2023, 787 characters The US Food and Drug Administration (FDA) has completed a submission review of Valneva’s biologics license application for single-shot chikungunya vaccine candidate VLA1553 and determined that the application is sufficiently complete to permit a substantive review. The review classification is “priority,” Valneva says. According to Valneva, late August 2023 has been assigned … Read more